Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the closing of its previously announced registered direct offering of an aggregate of 15,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 15,000,000 shares of common stock, at a purchase price of $1.00 per share of common stock and accompanying warrant to purchase one share of common stock. The warrants have an exercise price of $1.10 per share, will become exercisable on the six-month anniversary from the date of issuance and expire on the date that is five years after the date of issuance.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks